As he prepares to take on his newest volunteer role with the ACR, leading the Government Affairs Committee (GAC), Angus Worthing, MD, FACR, FACP, is looking forward to making the most of the opportunities that a unified government can offer the ACR in advocating for rheumatology care.
Also by this Author
“Advocacy is an investment in our profession—regardless of political leaning. A unified government offers great opportunities to get legislation passed that can support our practice and our patient care,” he says.
Advocating in Washington
With Congress signaling an increase in funding to the National Institutes of Health, Dr. Worthing hopes that more funds will be directed toward important research for advancements in rheumatology treatment. In broader efforts to advance research in Washington, he plans to speak up for rheumatology-related research at other federal agencies, such as the Centers for Disease Control and Prevention and the Department of Defense.
He’s also prepared to advance a rheumatology political agenda to other agencies in Washington, D.C. At the Food and Drug Administration, he will advocate for the effective management of biosimilar pharmaceuticals that can positively and cost-effectively affect the lives of rheumatology patients. Signals remain mixed about whether the Medicare Part B demonstration project will go forward, but Dr. Worthing hopes the ACR’s efforts will be fruitful and that the Centers for Medicare & Medicaid Services will support coverage of high-cost rheumatology medications; other items he will advocate for include realistic pay structures and payment models and practice support for rheumatologists paving new roads in advanced care.